Redeye updates its estimates following Surgical Science’s Q2 2025 report, which aligned with the company’s profit warning and broadly underperformed our original projections. While we believe coming quarters should present better figures, we lower our estimates and valuation. Despite worse-than-expected short-term development, we judge Surgical Science’s long-term potential remains essentially unchanged.
LÄS MER
